Research Article
Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases
Table 3
Characteristics of patients who developed new vertebral fractures during the study period.
| | Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| | Age at fracture, (years) | 34 | 49 | 73 | 68 | 75 | 52 | 65 | 44 | | Underlying disease | SLE | MCTD, HPS | PM | ILD | PMR | SLE, APS | SLE | TAK | | Age at onset (years) | 13 | 40 | 72 | 64 | 72 | 23 | 35 | 22 | | Disease duration (years) | 21 | 9 | 1 | 4 | 3 | 29 | 30 | 22 | | Max. glucocorticoid dose (mg) | 30 | 90 | 65 | 30 | 15 | 40 | 15 | 40 | | Glucocorticoid dose at fracture (mg) | 20 | 10 | 13 | 6 | 5 | 8 | 10 | 13 | | Osteoporosis treatment | None | D3 | BisP | BisP | BisP | BisP + D3 | BisP | BisP | | Osteoporosis treatment duration (months) | NA | 6 | 10 | 19 | 26 | 114 | 42 | 180 |
| | BMD, % YAM | | Lumbar spine | 65 | 93 | 84 | 73 | 86 | 91 | 73 | 99 | | Femoral neck | 60 | 84 | 83 | 75 | 81 | 87 | 90 | 83 |
| | Glucocorticoid-induced osteoporosis score | | Lumbar spine | 8 | 4 | 8 | 7 | 5 | 6 | 10 | 11 | | Femoral neck | 8 | 4 | 8 | 7 | 5 | 6 | 8 | 11 | | Prior fragility fracture | No | No | No | No | No | No | No | Yes |
|
|
SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; HPS, hemophagocytic syndrome; PM, polymyositis; ILD, interstitial lung disease; PMR, polymyalgia rheumatica; APS, antiphospholipid syndrome; TAK, Takayasu arteritis; BMD, bone mineral density; YAM, young adult mean; D3, active vitamin D3; BisP, bisphosphonate.
|
